{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:29:44Z","timestamp":1787138984938,"version":"build-2736575974"},"reference-count":39,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/RLF\/Re-entry\/44\/2018"],"award-info":[{"award-number":["BT\/RLF\/Re-entry\/44\/2018"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["CRG\/2020\/001213"],"award-info":[{"award-number":["CRG\/2020\/001213"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/12\/2025-01308"],"award-info":[{"award-number":["EMDR\/SG\/12\/2025-01308"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRP\/SG-2387\/2023"],"award-info":[{"award-number":["IIRP\/SG-2387\/2023"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006593","name":"Board of Research in Nuclear Sciences","doi-asserted-by":"publisher","award":["54\/14\/03\/2022-BRNS\/10207"],"award-info":[{"award-number":["54\/14\/03\/2022-BRNS\/10207"]}],"id":[{"id":"10.13039\/501100006593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"VIT SEED GRANT","doi-asserted-by":"publisher","award":["202021, 20212023"],"award-info":[{"award-number":["202021, 20212023"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The folate receptors (FR) are highly overexpressed in various solid tumors and metastatic cancers, whereas they are low or negligible in healthy cells. This provides a window of opportunity to deliver any payload by specifically targeting these receptors. This study develops a delivery strategy for exatecan (payload), a Top1 inhibitor, via the Fol-SS-Exa (8) conjugate, demonstrating its potency against FR-positive cancer cells in vitro and in preclinical studies. The design of the Fol-SS-Exa (8) conjugate features folate as a ligand targeting FR\u03b1 and a cleavable disulfide linker that remains stable under physiological conditions. Exatecan (6), a highly potent cytotoxic payload, arrests cell division in cancer cells. Fol-SS-Exa (8) exhibited an IC50 value of 4.88 nM in the FR-positive MDA-MB-231 cell line. The Fol-SS-Exa conjugate (8), administered to tumor-induced C57BL\/6 mice, exhibited complete regression after three injections (7.5 mg\/kg body weight), highlighting its potent antitumor activity. In addition, the conjugate (8) demonstrated the ability to eradicate the toxicity of exatecan (6) when administered alone.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00330","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:12:51Z","timestamp":1784045571000},"page":"1720-1730","source":"Crossref","is-referenced-by-count":1,"title":["Receptor-Targeted\nFolic Acid Ligand\u2013Drug Conjugate\nof Exatecan Leads to Complete Tumor Regression in the Preclinical\nTumor Model"],"prefix":"10.1021","volume":"37","author":[{"given":"Dhanashree","family":"Murugan","sequence":"first","affiliation":[{"name":"Vellore Institute of Technology (VIT) , , , ,","place":["Vellore, Tamil Nadu, India, 632014"]},{"name":"Vellore Institute of Technology (VIT) , , , ,","place":["Vellore, Tamil Nadu, India, 632014"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-0330","authenticated-orcid":true,"given":"Loganathan","family":"Rangasamy","sequence":"additional","affiliation":[{"name":"Vellore Institute of Technology (VIT) , , , ,","place":["Vellore, Tamil Nadu, India, 632014"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026081907213500800_cit1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1039\/C7SC04004K","article-title":"Advances in targeting the folate\nreceptor in the treatment\/imaging of cancers","volume":"9","author":"Ferna\u0301ndez","year":"2018","journal-title":"Chem. Sci."},{"key":"2026081907213500800_cit2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent progress of aptamer\u2013drug\nconjugates in cancer therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm. Sin.\nB"},{"key":"2026081907213500800_cit3","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1021\/acs.molpharmaceut.3c01049","article-title":"Small Molecule\u2013Drug\nConjugates Emerge as a New Promising Approach\nfor Cancer Treatment","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharmaceutics"},{"issue":"7","key":"2026081907213500800_cit4","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3561","article-title":"Small molecule\u2013\nand peptide\u2013drug conjugates\naddressing integrins: A story of targeted cancer treatment","volume":"30","author":"Paulus","year":"2024","journal-title":"J. Pept. Sci."},{"issue":"2","key":"2026081907213500800_cit5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ANTIB7020016","article-title":"Small-Format Drug Conjugates:\nA Viable Alternative to ADCs for Solid Tumours?","volume":"7","author":"Deonarain","year":"2018","journal-title":"Antibodies"},{"issue":"2","key":"2026081907213500800_cit6","doi-asserted-by":"publisher","first-page":"110960","DOI":"10.1016\/J.CCLET.2025.110960","article-title":"Cancer-targeting drug\nconjugates drives a new era in precise cancer treatment","volume":"37","author":"Deng","year":"2026","journal-title":"Chin. Chem. Lett."},{"key":"2026081907213500800_cit7","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1039\/D3SC05539F","article-title":"Package delivered: folate receptor-mediated transporters in cancer\ntherapy and diagnosis","volume":"15","author":"Ahmadi","year":"2024","journal-title":"Chem. Sci."},{"key":"2026081907213500800_cit8","doi-asserted-by":"publisher","first-page":"117829","DOI":"10.1016\/j.ejmech.2025.117829","article-title":"PSMA targeted Therapy: From molecular\nmechanisms to clinical breakthroughs in castration-resistant prostate\ncancer","volume":"296","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"2026081907213500800_cit9","doi-asserted-by":"publisher","first-page":"120082","DOI":"10.1016\/J.IJPHARM.2020.120082","article-title":"EGFR targeting for cancer therapy: Pharmacology and\nimmunoconjugates with drugs and nanoparticles","volume":"592","author":"Santos","year":"2021","journal-title":"Int. J. Pharm."},{"key":"2026081907213500800_cit10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","article-title":"The role of\nHER2 in cancer therapy\nand targeted drug delivery","volume":"146","author":"Tai","year":"2010","journal-title":"J. Controlled Release"},{"key":"2026081907213500800_cit11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.7150\/thno\/v01p0154","article-title":"Integrin Targeted\nTherapeutics","volume":"1","author":"Millard","year":"2011","journal-title":"Theranostics"},{"key":"2026081907213500800_cit12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","article-title":"Emerging roles for folate receptor FOLR1 in signaling\nand cancer","volume":"33","author":"Nawaz","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"2026081907213500800_cit13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.18632\/oncotarget.412","article-title":"Characterization\nof the Human Folate Receptor Alpha Via Novel Antibody-Based Probes","volume":"2","author":"O\u2019Shannessy","year":"2011","journal-title":"Oncotarget"},{"key":"2026081907213500800_cit14","unstructured":"Study Details | NCT01689766 | Study Using FolateScan\nto Identify\nSubjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma\n| ClinicalTrials.gov.; https:\/\/www.clinicaltrials.gov\/study\/NCT01689766, (Accessed 20 Jan 2026)."},{"issue":"1","key":"2026081907213500800_cit15","doi-asserted-by":"publisher","first-page":"12772","DOI":"10.1038\/s41598-020-69682-9","article-title":"Pre-clinical studies of EC2629, a highly potent\nfolate- receptor-targeted DNA crosslinking agent","volume":"10","author":"Reddy","year":"2020","journal-title":"Sci. Rep."},{"key":"2026081907213500800_cit16","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1038\/s41598-018-27320-5","article-title":"Pre-clinical evaluation\nof EC1456,\na folate-tubulysin anti-cancer therapeutic","volume":"8","author":"Reddy","year":"2018","journal-title":"Sci. Rep."},{"key":"2026081907213500800_cit17","unstructured":"Study Details | NCT04740398 | A Study of CBP-1008\nin Patients With\nAdvanced Solid Tumor | ClinicalTrials.gov.; https:\/\/clinicaltrials.gov\/study\/NCT04740398?cond=CBP-1008&rank=1, (Accessed 20 Jan 2026)."},{"key":"2026081907213500800_cit18","unstructured":"CBP-1008 Gets Clinical\nApproval by FDA \u2013 CBP; https:\/\/www.coherentbio.com\/news\/cbp-1008-gets-clinical-approval-by-fda\/, (Accessed 20 Jan 2026)."},{"key":"2026081907213500800_cit19","unstructured":"Study Details | NCT05830097\n| A Study of Bi-Ligand-Drug Conjugate\nCBP-1019 in Patients With Advanced Solid Tumors | ClinicalTrials.gov.; https:\/\/www.clinicaltrials.gov\/study\/NCT05830097, (Accessed 20 Jan 2026)."},{"key":"2026081907213500800_cit20","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.annonc.2024.08.714","article-title":"648P An open-label,\nMRCT phase I\/II\nstudy evaluating the safety, tolerability, pharmacokinetics and preliminary\nefficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients\n(pts) with advanced solid tumors","volume":"35","author":"Liu","year":"2024","journal-title":"Ann. Oncol."},{"key":"2026081907213500800_cit21","unstructured":"Study Details | NCT04928612 | A Study of CBP-1018\nin Patients With\nAdvanced Solid Tumors | ClinicalTrials.gov.; https:\/\/clinicaltrials.gov\/study\/NCT04928612?cond=CBP-1018&rank=1, (Accessed 20 Jan 2026)."},{"key":"2026081907213500800_cit22","unstructured":"An open-label, non-randomized,\nmulti-center phase I study evaluating\nthe safety, tolerability, pharmacokinetics and preliminary efficacy\nof bi-ligand-drug conjugate CBP-1018 in patients with advanced solid\ntumors. - ASCO; https:\/\/www.asco.org\/abstracts-presentations\/213062\/poster,\n(Accessed 20 Jan 2026)."},{"key":"2026081907213500800_cit23","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.biomaterials.2013.01.041","article-title":"A pH-sensitive\ndoxorubicin\nprodrug based on folate-conjugated BSA for tumor-targeted drug delivery","volume":"34","author":"Du","year":"2013","journal-title":"Biomaterials"},{"key":"2026081907213500800_cit24","doi-asserted-by":"publisher","first-page":"15792","DOI":"10.1039\/C5CC05294G","article-title":"A dendritic \u03b2-galactosidase-responsive\nfolate-monomethylauristatin e conjugate","volume":"51","author":"Alsarraf","year":"2015","journal-title":"Chem.\nCommun."},{"key":"2026081907213500800_cit25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1021\/bc500146p","article-title":"Development of a Folate\nReceptor (FR)-Targeted Indenoisoquinoline\nUsing a pH-Sensitive N-Ethoxybenzylimidazole (NEBI) Bifunctional Cross-Linker","volume":"25","author":"Cao","year":"2014","journal-title":"Bioconjugate Chem."},{"issue":"3","key":"2026081907213500800_cit26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1021\/bc400441s","article-title":"Folate\u2013Vinca Alkaloid Conjugates for Cancer\nTherapy: A Structure\u2013Activity Relationship","volume":"25","author":"Leamon","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"2026081907213500800_cit27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/2767-9764.CRC-22-0517","article-title":"A Very\nLong-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors","volume":"3","author":"Fontaine","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"2026081907213500800_cit28","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1200\/jco.2004.22.90140.4005","article-title":"Phase III results of\nexatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-nai\u0308ve\npatients with advanced pancreatic cancer (APC)","volume":"22","author":"Cheverton","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2026081907213500800_cit29","doi-asserted-by":"publisher","first-page":"1900531","DOI":"10.1002\/marc.201900531","article-title":"Disulfide-Based\nSelf-Immolative Linkers and Functional\nBioconjugates for Biological Applications","volume":"41","author":"Deng","year":"2020","journal-title":"Macromol.\nRapid Commun."},{"key":"2026081907213500800_cit30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/S13321-018-0283-X","article-title":"ADMETlab: a platform\nfor systematic ADMET evaluation based on a comprehensively collected\nADMET database","volume":"10","author":"Dong","year":"2018","journal-title":"J. Cheminf."},{"key":"2026081907213500800_cit31","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0:\nan integrated online platform for accurate\nand comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"2026081907213500800_cit32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated\nendocytosis and intracellular trafficking dynamics in the development\nof antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"issue":"1","key":"2026081907213500800_cit33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of Antibody-Drug\nConjugates in Cancer Cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer\nRes."},{"key":"2026081907213500800_cit34","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.2147\/DDDT.S344052","article-title":"Dynamics of Endocytosis\nand Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive\nCancer Cells","volume":"15","author":"Liang","year":"2021","journal-title":"Drug Des., Dev. Ther."},{"issue":"15","key":"2026081907213500800_cit35","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/J.BMCL.2019.05.047","article-title":"Folic acid\nconjugates of a bleomycin mimic for selective targeting of folate\nreceptor positive cancer cells","volume":"29","author":"Geersing","year":"2019","journal-title":"Bioorg. Med.\nChem. Lett."},{"key":"2026081907213500800_cit36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/aps.2016.151","article-title":"Molecular design and\nsynthesis of self-assembling camptothecin drug amphiphiles","volume":"38","author":"Cheetham","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"43","key":"2026081907213500800_cit37","doi-asserted-by":"publisher","first-page":"28375","DOI":"10.1021\/ACSOMEGA.0C04395","article-title":"Amphiphilic\nSmall-Molecule Assemblies to Enhance the Solubility and Stability\nof Hydrophobic Drugs","volume":"5","author":"Gangarde","year":"2020","journal-title":"ACS Omega"},{"key":"2026081907213500800_cit38","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2147\/IJN.S490444","article-title":"How Advanced are Self-Assembled\nNanomaterials for Targeted Drug Delivery? A Comprehensive Review of\nthe Literature","volume":"20","author":"Nsairat","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"2026081907213500800_cit39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-003-0696-7","article-title":"A phase II\nstudy of intravenous exatecan mesylate (DX-8951f) administered daily\nfor 5 days every 3 weeks to patients with advanced ovarian, tubal\nor peritoneal cancer resistant to platinum, taxane and topotecan","volume":"53","author":"Verschraegen","year":"2004","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00330","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1720\/65920654\/acs.bioconjchem.6c00330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1720\/65920654\/acs.bioconjchem.6c00330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:22:23Z","timestamp":1787138543000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/8\/1720\/5208774\/Receptor-Targeted-Folic-Acid-Ligand-Drug-Conjugate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00330","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}